Feature

Rayner Expands US Cataract Platform with Anikavisc Acquisition

Strengthens Rayner’s US cataract portfolio with a fully bundled OVD, IOL and phaco offering

  • March 13, 2026

  • 2 min

Share

  • 1

    Rayner acquired US rights to Anikavisc from Visco Technologies.

  • 2

    Anikavisc OVD supports cataract surgeries.

  • 3

    Rayner launched its Sophi phaco platform.

  • 4

    Anikavisc enhances Rayner's IOL product offerings.

  • 5

    Customers will not see changes to existing arrangements.

  • 6

    The acquisition streamlines purchasing and offers bundled solutions.

  • 7

    Rayner plans to introduce AI-designed IOL technology by 2026.

Original Source(s)

Rayner Expands US Cataract Platform with Anikavisc Acquisition

  • March 13, 2026

Related Content

Hydrus®: Designed with Purpose

Professor Norbert Pfeiffer explores the features and benefits of the Hydrus® Microstent

  • March 13, 2026

  • 4 min
Lipid-Derived Biomarkers for NAION

TVST study reveals potential new metabolic signal in nonarteritic anterior ischemic optic neuropathy

  • March 13, 2026

  • 4 min
Cataract Surgeons Gain a New Lens Tool

An extended depth of focus intraocular lens approved by the FDA is designed to improve visual range while maintaining contrast sensitivity in cataract surgery.